Upperton Pharma Solutions has completed the building of its new development and GMP manufacturing facility with an investment of US$19 million (£15m).
The newly established facility encompasses ten advanced GMP manufacturing suites, as well as quality control laboratories and formulation development areas featuring pilot plant capabilities.
The facility encompassing 50,000 square feet, has been thoughtfully designed to expand operational capabilities.
The facility boasts a comprehensive capacity to handle highly potent and controlled pharmaceuticals across various dosage forms. Its capabilities span from early formulation development to the provision of clinical trial supplies from Phase 1 to Phase 3.
This expansion results in a substantial augmentation of the manufacturing space, growing from 1,300 square feet to an impressive 13,000 square feet. Similarly, the analytical laboratory area has undergone a remarkable increase from 880 square feet to a spacious 8,500 square feet.
The facility will be full operation by fourth quarter of 2023 for development and non-GMP manufacturing, aiming to initiate GMP operations by January 2024.
Name Upperton Pharma Solutions
Type New Construction
Budget US$19 million (£15m)